Life Science & Biotech

Dow Agrosciences introduces genetically modified corn seedRestricted Content

July 27, 2009
 IBJ Staff
Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow its seed sales substantially.
More

Potential obesity breakthrough boosts Marcadia

July 20, 2009
J.K. Wall
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
More

Professors go online to revolutionize drug discoveryRestricted Content

July 20, 2009
 IBJ Staff
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
More

Lilly cancer drug OK'd for new use

July 6, 2009
J.K. Wall
Eli Lilly and Co.'s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer for certain patients, Lilly announced today.
More

Minority suppliers diversifying into life sciencesRestricted Content

July 6, 2009
Scott Olson
The Indiana Minority Supplier Development Council has made life sciences companies its latest target—part of an even larger effort to attract minorities to the burgeoning life sciences industry under way on a national scale.
More

Board battle brewing at BioanalyticalRestricted Content

June 29, 2009
 IBJ Staff
West Lafayette-based life sciences contract research firm Bioanalytical Systems Inc. has five directors on its board. If company founder Pete Kissinger has his way, four of them will soon be replaced.
More

Profs trying to revolutionize drug discovery processRestricted Content

June 22, 2009
 IBJ Staff
Two chemistry professors at IUPUI are laboring to create the McDonald's of research laboratories—a model that's low-cost and can spread around the world.
More

Bioanalytical Systems founder fights to be heardRestricted Content

May 4, 2009
Peter Schnitzler
It took Pete and Candace Kissinger 33 years to build West Lafayette-based Bioanalytical Systems Inc. into one of the largest contract research firms in Indiana's life science sector. It took just a year and a half for them to turn against the company's new management.
More

With pharma famine looming, Lilly relying on snack-size dealsRestricted Content

May 4, 2009
J.K. Wall
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year, Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
More

Stem cell discovery promises health care revolutionRestricted Content

April 13, 2009
Bloomberg News
Scientists are using a new stem-cell technique that may someday revolutionize care for disorders as diverse as diabetes, Alzheimer's disease and muscular dystrophy.
More

Indiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individualsRestricted Content

April 13, 2009
Chris O'Malley
Indiana is becoming not only a hotbed of "pharmacogenomics" research, but also a trailblazer in finding practical ways to use it on the practitioner level.
More

Linking specialties is key to life sciencesRestricted Content

March 30, 2009
The Indiana Innovation Alliance will bring together researchers from both IU and Purdue and keep much intellectual property innovation in Indiana.
More

Executives make many trips to Washington to argue for 14 years of sales exclusivity for new drugs made from cellsRestricted Content

March 23, 2009
J.K. Wall
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made from cells.
More

Medical, tech entrepreneurs launch matchmaking effort in life sciencesRestricted Content

March 16, 2009
Chris O'Malley
Three entrepreneurs from the medical and software realms are herding angels to invest in upstart life sciences companies in Indiana.
More

Attorneys with doctorates in high demandRestricted Content

March 16, 2009
Scott Olson
Lawyers holding doctorates in biotech, biology, chemistry and computer sciences are in high demand by firms with strong intellectual property practices.
More

Dow may need to sell Indy's Dow AgroSciencesRestricted Content

February 16, 2009
Peter Schnitzler
Financially strapped Dow Chemical Co. acknowledges it may sell Indianapolis-based Dow AgroSciences LLC, the ag-chemicals-and-biotech firm that's one of the biggest jewels in the city's life sciences crown.
More

Advanced energy next focus for economic developmentRestricted Content

February 16, 2009
Chris O'Malley
The Central Indiana Corporate Partnership—the parent of the BioCrossroads, TechPoint and Conexus industry cluster initiatives—let it be known last month that there would be a fourth leg to its economic development stool: clean technology.
More

NASA contracts soaringRestricted Content

February 9, 2009
Chris O'Malley
NASA begins to award more grants to Indiana firms and universities.
More

Biotech push may help offset generic competition; some analysts skepticalRestricted Content

February 2, 2009
J.K. Wall
Lilly executives want to make biotech their top focus.
More

Carmel startup lands $12M in venture capitalRestricted Content

January 19, 2009
Peter Schnitzler
Carmel startup Waterstone Pharmaceuticals Inc., which hopes to research drug components here and make them in China, has just raised $12 million in venture capital—despite the recession and a deep freeze in financial markets.
More

OBS Medical hopes to capture pharma's heartRestricted Content

January 19, 2009
J.K. Wall
The latest product to come out of Carmel-based OBS Medical may be just what the doctors ordered. The doctors working for major pharmaceutical companies, that is.
More

Grants will shrink, life sciences leader predictsRestricted Content

January 19, 2009
Scott Olson
Last fall, BioCrossroads named Leonard J. Betley—chairman of the Richard M. Fairbanks Foundation, the Regenstrief Foundation and the Walther Cancer Foundation—its inaugural Life Sciences Champion of the Year. IBJ recently caught up with Betley to get his thoughts on the latest life sciences developments and gauge the climate for fund raising.
More

Targanta receives rescue line for drugRestricted Content

January 19, 2009
A former Eli Lilly and Co. antibiotic being developed in Indianapolis will live to try again. The company developing the drug, Massachusetts-based Targanta Therapeutics Inc., has agreed to be acquired by New Jersey-based The Medicines Co. for $42 million.
More

State's tech sector looking ahead, but cutting backRestricted Content

January 12, 2009
It's two steps forward, one step back, for Indiana's technology sector, but in a tough economic climate, any advancement is worth celebrating.
More

Biotech venture fund in worksRestricted Content

January 5, 2009
Peter Schnitzler
BioCrossroads is setting the stage to create Indiana Future Fund II, an effort that would raise tens of millions of dollars for speculation on promising Hoosier life science companies.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. why oh why does this state continue to elect these people....do you wonder how much was graft out of the 3.8 billion?

  2. i too think this is a great idea. I think the vision and need is there as well. But also agree with Wendy that there may be better location in our city to fulfill this vision and help grow the sports of hockey and figure skating in Indy. Also to help further develop other parts of the city that seem often forgotten. Any of the other 6 townships out side of the three northernmost could benefit greatly from a facility and a vision like this. For a vision that sounds philanthropic, the location is appears more about the money. Would really like to see it elsewhere, but still wish the development the best of luck, as we can always use more ice in the city. As for the Ice growth when they return, if schedules can be coordinated with the Fuel, what could be better than to have high level hockey available to go see every weekend of the season? Good luck with the development and the return of the Ice.

  3. How many parking spaces do they have at Ironworks? Will residents have reserved spaces or will they have to troll for a space among the people that are there at Ruth Chris & Sangiovese?

  4. You do not get speeding ticket first time you speed and this is not first time Mr.Page has speed. One act should not define a man and this one act won't. He got off with a slap on the wrist. I agree with judge no person was injured by his actions. The state was robbed of money by paying too much rent for a building and that money could have been used for social services. The Page family maybe "generous" with their money but for most part all of it is dirty money that he obtained for sources that are not on the upright. Page is the kind of lawyer that gives lawyers a bad name. He paid off this judge like he has many other tine and walked away. Does he still have his license. I believe so. Hire him to get you confiscated drug money back. He will. It will cost you.

  5. I remain amazed at the level of expertise of the average Internet Television Executive. Obviously they have all the answers and know the business inside and out.

ADVERTISEMENT